BALAXI PHARMACEUTICALS LIMITED

rs,

euticals Limited c. Chinta Shalini Company Secretary Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee -lills, Phase-Ill, Hyderabad, Telangana, India - 500096. CIN:L25

Rs.10

it or loss Total comprehensive income for the period Paid up equity share capital- Face value of Rs.10 each Other Equity Earnings Per Share (EPS) (EPS for the quarter is not annualised) -Basic (Amo

Rs. 8349.72Lakh

sidiary, whose interim financial results and other financial information reflect total revenues of Rs. 8349.72Lakhs, total net profit after tax of Rs. 1512.S0Lakhs and comprehensive income of Rs. 1399.60Lakhs for

Rs. 1512

er financial information reflect total revenues of Rs. 8349.72Lakhs, total net profit after tax of Rs. 1512.S0Lakhs and comprehensive income of Rs. 1399.60Lakhs for the quarter ended June 30,2022, as consi

0Lakh

al information reflect total revenues of Rs. 8349.72Lakhs, total net profit after tax of Rs. 1512.S0Lakhs and comprehensive income of Rs. 1399.60Lakhs for the quarter ended June 30,2022, as considered

Rs. 1399.60Lakh

es of Rs. 8349.72Lakhs, total net profit after tax of Rs. 1512.S0Lakhs and comprehensive income of Rs. 1399.60Lakhs for the quarter ended June 30,2022, as considered in the Statement whose interim financial resul

400 billion

up for its product lines. 8 Global Footprint Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled pr

6 billion

al Footprint Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 9 Key Milestones Started business supplying white labelled products to customers in Africa Pr

42%

– Dominican Republic 14 FINANCIAL HIGHLIGHTS 15 Management’s Comments “Our revenue growth of 42% during Q1 is driven by strong volume contribution from Latin American markets. We have also derive

Rs. 85 crore

atin American markets where we are rapidly gaining visibility. The estimated project investment of Rs. 85 crore will be financed partly from internal accruals and a judicious mix of additional capital. With the

106%

yback apart from several strategic benefits for the business from this investment.” 42% Revenues 106% Gross Profit 21% EBITDA 32% Profit After Tax 50% Return on Equity Debt Free Ashish Maheshwari

21%

veral strategic benefits for the business from this investment.” 42% Revenues 106% Gross Profit 21% EBITDA 32% Profit After Tax 50% Return on Equity Debt Free Ashish Maheshwari Chairman & Manag

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“Going forward, as business scales up, we expect a positive contribution to revenue growth as well as geographical diversification.”

“85 crore will be financed partly from internal accruals and a judicious mix of additional capital.”

“Going forward, as business scales up, we expect a positive contribution to revenue growth as well as geographical diversification.”

“90 crore will be financed partly from internal accruals and a judicious mix of additional capital.”

Notes

2

Registered Office

1

Established operations

1

Expansion initiated

1

Financial Highlights

1

About Balaxi Pharmaceuticals Limited

1

Disclaimer

1

Registered Office

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee -lills, Phase-Ill, Hyderabad, Telangana, India - 500096. CIN:L251S1TG1942PLC121598 Phone: +91 40 23555300 Email: info@balaxi.in I Website: www.balaxipharma.in ANNEXtJRE -1 Balaxi Pharmaceuticals Limited 2nd Floor, :VL-\PS Towers, Plot no. 409, Road no. 81, Jubilee Hils, Phase Ill, Hvderabad-500096, Telangana Cl:-J:L25 l 91 TGl 942PLC121598 Un-audited Consolidated Financial Results for the quarter ended 30th June, 2022 Particulars Income Revenue fron1 operations Other income Total Income Expenses Cost of materials consumed Employee benefit expense Findnce cost Depreciation and amortisation expense Administrative Expenses Total Exoenses Profit/(loss) before tax and other comprehensive Tax expenses Current tax Deferred tax Net Profit/(loss) for the period Other comprehensive income A (i) Items that will not be reclassified to profit or loss in subsequent period income Exchange differences on translation of foreign operations (ii) I

Notes

1. The un-audited Consolidated Financial Results for the quarter ended 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on 2nd August, 2022. The Consolidated Financial Results are prepared with the [ndian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. in accordance 2. Previous period figures have been regrouped, classification. re-arranged and re-dassified wherever necessary to conform to current period's 3. The operating segment of the Group is identified as "Specialized Wholesale" as the Management overall level as one segment. Therefore, Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company the disclosure as per Regulation 33 (l)(e) read with Clause L of Schedule IV of the SEBI (Listing reviews business performance at an 4. Financial Results for Quarter ended 30.06.2022 are not strictly comparable with Financial Results for the Quarter

Notes

30.06.2022 (Unaudited) Quarter Ended 31.03.2022 (Audited) 30.06.2021 (Unaudited) (Rs. in Lakhs) Year ended 31.03.2022 (Audited) 2,6-!5.36 257.19 2,902.55 1,995.58 111.50 19.64 7.96 11-!.59 2,249.27 653.28 120.12 (0.36) 533.52 - - - 2,06-!.69 107.10 2,171.79 1,486.91 77.98 2.12 7.80 109.32 1,684.13 487.66 134.32 0.70 352.64 - - - - - 533.52 1,000.00 - 352.64 1,000.00 2,918.04 99.19 3,017.23 2,267.55 60.31 0.25 2.63 93.08 2,423.82 593.41 150.23 (0.07) 443.25 10,129.19 274.81 10,404.00 7,691.92 289.88 6.12 25.03 421.18 8,434.13 1,969.87 499.95 3.18 1,466.74 - - - - 443.25 1,000.00 1,466.74 1,000.00 4,791.30 5.3-! 5.3-! 3.53 3.53 4.43 4.43 14.67 14.67 1. The un-audited Standalone Financial Results for the quarter 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on 2nd August, 2022. The Standalone Financial Results are prepared Act, 2013. in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Sectio

Established operations

Guatemala (Latin America), Dominican Republic (Caribbean) and Angola (Africa) New operations: Honduras (Latin America)

Expansion initiated

El Salvador, Nicaragua, Ecuador, Chile (Latin America) Central African Republic, Zambia (Africa) Products Vast range of essential OTC medicines – with healthy mix of generics and branded generics 649 product registrations in five countries 625 registrations submitted or in the pipeline Supply Chain Outsourced production from WHO GMP certified plants in India, China and Portugal Establishing EU GMP compliant facilities in Hyderabad Distribution Deep presence through 37 warehouses and on-ground fleet support Transformation New initiatives strengthening functionality in supply chain, regulatory affairs and customer service Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools 5 Key Success Factors Market Selection Methodology  Focus on countries with high-potential economic growth framework  Identify non-English speaking countries with

Financial Highlights

Particulars (INR Crore) Revenue Gross Profit Gross Margin % EBITDA EBITDA Margin % Profit After Tax PAT Margin % Earnings Per Share (INR) Q1FY23 82.78 34.52 41.7% 17.03 20.6% 14.15 17.1% 14.15 Q1FY22 58.34 16.8 28.8% 12.55 21.5% 10.71 18.4% 10.71 YoY +41.9% +105.5% 1,290 bps +35.6% (95) Bps +32.1% (127) Bps +32.1% Quarterly Financial Results for Quarter ending 30.6.22 are not strictly comparable with Quarter ending 30.6.21 due to the consolidation of Balaxi Healthcare LDA Angola (BHA) which became a wholly owned subsidiary of Balaxi Global DMCC with effect from 1st January 2022. • Revenue: The strong growth in revenue of 41.9% YoY in Q1FY23 was driven by the Pharmaceuticals business, with the LATAM share increasing to 38%. • EBITDA: EBITDA of INR 17.03 Cr. was recorded in Q1 FY23, registering 35.6% growth YoY, as the Company, despite the cost structures in new geographies incurred ahead of commercial launches in these countries. • Profit After Tax: On the back of strong performance of